A recent study indicates that people who come off popular GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds far faster than those who end conventional lifestyle programs.
Published data in a prominent medical journal points out that while obese people can lose a large proportion of their total mass while undergoing treatment, the weight returns at an estimated rate of 0.8 kg per month upon discontinuation.
"Individuals buying such treatments should be cognizant of the potential of quick rebound weight gain when the medication is stopped," cautioned expert Dr. Susan Jebb.
This pace of regain implies a return to starting weight in about a year and a half.
Weighing Treatments
The analysis, which reviewed 37 of trials involving thousands of participants, compared the effects of the injectable medications with conventional dieting.
The team point out that individuals who shed pounds through lifestyle changes alone typically have a slower creep back—approximately 100 grams monthly—after stopping.
Understanding the Rapid Rebound
Doctors suggest the mode of action of the injections is key to understanding the amplified rebound.
GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Sustained high doses of GLP-1 levels far above than normal may cause the body to produce less of its own natural hormone, and could reduce responsiveness to its actions," noted Dr. Adam Collins, a dietetics expert.
"Withdrawal of this GLP-1 'fix' results in hunger is uncontrolled, making overeating a significant risk."
An Ongoing Condition?
Medical guidelines suggest the jabs for individuals with obesity-related medical conditions, alongside prescribed lifestyle changes.
Many experts contend that, due to the significant potential of weight regain, the therapy should be considered long-term.
This opinion is reinforced by drug manufacturers, who say that the findings "highlight the long-term nature of excess weight," akin to managing diseases like high blood pressure.
Patient Accounts
Users who have come off the jabs report a intense return of hunger.
"It was like something flipping and you become starving," described a patient.
This difficulty is compounded if patients have not developed lasting lifestyle or habit changes during treatment.
Widespread Interest
Recent estimates suggest that a significant number of adults in the UK have tried weight-loss jabs in the past year, with desire remaining high.
- Use is greater among females than men.
- The middle-aged age group shows the greatest usage rates.
- A large proportion obtain the medications through private prescriptions rather than public health services.
Finally, clinicians caution that while GLP-1 drugs are effective tools for shedding pounds, they are not a magic solution and lasting health benefits relies on combined lifestyle management.
